Modeling of the pH-and the temperature-dependant deviations of the free to total PSA (Prostate Specific Antigen) ratios for clinical predictability of prostate cancer and benign prostate hyperplasia
Tóm tắt
Both the free and total PSA had been reported to be pH-and temperature-labile. We have introduced two submodels to describe the decay of PSAs. The overall pH-dependent decay model (OPDDM) describes the ratio of free to true scientific total PSA including both the immunoreactive and the nonimmunoreactive. We elucidated four pH-dependent formation constants for the free PSA with hydronium ion [H+], the PSA-ACT (α
1-antichymotrypsin), the PSA-API (α
1-protease inhibitor), and the nonimmunoreactive PSA-AMG (α
2-macroglobulin) complexes, respectively, to model the stability of the free to total PSA ratios. Model simulation indicated a highly pH-sensitive behavior of the free to total PSA ratios. While the temperature dependent decay model (TDDM) indicated that kinetically, free PSA revealed the most rapid decay rates due to its low activation energy, total PSA was shown to be relatively more thermally stable. The decay of all PSA species could be more accelerated at temperatures higher than −4°C, while it is kept below −70°C throughout. It is thus recommended to use the preparation fresh (better within 8 h) after venipuncture. And it is advisable that all the results are advised to perform corrections for each determination by calculating back to the data at the original physiological pH prior to clinical diagnostic interpretation.
Tài liệu tham khảo
Arcangeli, C. G., D. S. Smith, T. L. Ratliff and W. J. Catalona (1997). Stability of serum total free prostate specific antigen under varying storage intervals and temperatures. J. Urol. 158, 2182–2187.
Bailey, J. E. and D. F. Ollis (Eds), (1986a). Biochemical Engineering Fundamentals, Chemical Engineering Series, 2nd edn, McGraw-Hill International Editions, p. 747.
Bailey, J. E. and D. F. Ollis (Eds), (1986b). Biochemical Engineering Fundamentals, Chemical Engineering Series, 2nd edn, McGraw-Hill International Editions, pp. 441–445, p. 587.
Barrett, A. J., M. A. Brown and C. A. Sayers (1979). The electrophoretically ’slow’ and ‘fast’ forms of the alpha-2-macroglobulin molecule. Biochem. J. 181, 401–418.
Cartledge, J. J., D. Thompson, H. Verril, P. Clarkson and I. Eardley (1999). The stability of free and bound prostate-specific antigen. B. J. U. International 84, 810–814.
Chen, Z., A. Prestigiacomo and T. A. Stamey (1995). Purification and characterization of prostate-specific antigen (PSA) complexed to α 1-antichymotrypsin: Potential reference materials for international standardization of PSA immunoassays. Clin. Chem. 41, 1273–1282.
Christensson, A., T. Bjork, O. Nilsson, U. Dahlen, M-T. Matikainen and A. T. K. Cockett et al. (1993). Serum prostate specific antigen complexed to α 1-antichymotrypsin as an indicator of prostate cancer. J. Urol. 50, 100–105.
Ganrot, P. O. and J. E. Nilehn (1967). Competition between plasmin and thrombin for alpha-2-macroglobulin. Clin. Chim. Acta. 17, 511–513.
Happer, H. A., V. W. Rodwell and P. A. Mayes (Eds), (1977). Review of Physiological Chemistry, 16th edn, Lange Medical Publications, p. 63.
Huber, P. R., H.-P. Schmid, G. Mattarelli, B. Strittmatter, G. J. V. Steenbrugge and A. Mauer (1995). Serum free prostate specific antigen: isozymes in benign hyperplasia and cancer of the prostate. The Prostate 27, 212–219.
Jung, K., M. Lein, B. Brux, P. Sinha, D. Schnorr and S. A. Loening (2000). Different stability of free and complexed prostate-specific antigen in serum in relation to specimen handling and storage conditions. Clin. Chem. Lab. Med. 38, 1271–1275.
Jung, K., P. von Klinggraff, B. Brux, P. Sinha, D. Schnorr and S. A. Loening (1998). Preanalytical determinations of total and free prostate-specific antigen and their ratio: blood collection and storage conditions. Clin. Chem. 44, 685–688.
Kioukia-Fougia, N., I. Christofidis and N. Strantzalis (1999). Physicochemical conditions affecting the formation/stability of serum complex and the determination of prostate-specific antigen (PSA). Anticancer Res. 19, 3315–3320.
Levenspiel, O. (Ed.), (1972). Chemical Reaction Engineering, 1st edn, Wiley International Edition, pp. 20–25. Chapter 2.
Lilja, H. (1985). A kallikrein serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J. Clin. Invest. 76, 1899–1903.
Lilja, H. (1997). Free and total PSA background information and rationale for use, in Recent Advances in Prostate Cancer and BPH, Wiley International Edition, H. S. Fritz (Ed.), The Parthenon Publishing Group, pp. 195–197.
McQuarrie, D. A. and J. D. Simon (Eds), (1997). Physical chemistry—a molecular approach. University Science Books, 55D Gate Five Road, Sausalito, CA 94965, USA, pp. 1072–1074.
Oesterling, J. E. (1991). Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol. 145, 907–923.
Paus, E., O. Nilsson, O. P. Bormer, S. D. Fossa, B. Otnes and E. Skovlund (1988). Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia. J. Urol. 159, 1599–1605.
Pettersson, K., T. Piironen, M. Seppala, L. Liukkonen, A. Christensson and M. T. Matikainnen et al. (1995). Free and complexed prostate-specific antigen (PSA): In vitro stability, epitopes maps, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-α 1-antichymotrypsin complex. Clin. Chem. 41, 1480–1488.
Sensabaugh, G. E. and E. T. Blake (1990). Seminal plasma protein p30: simplified purification and evidence for identity with prostate-specific antigen. J. Urol. 144, 1523–1526.
Shanbhag, V. P., T. Stigbrand and P. E. Jensen (1997). The contact zones in human alpha-2-macroglobulin—functional domains important for the recognition of the trapping mechanism. Eur. J. Biochem. 244, 694–699.
Simm, B. and M. Gleeson (1991). Storage conditions for serum for estimating prostate-specific antigen. Clin. Chem. 37, 113–114.
Sottrup-Jensen, L. (1989). Alpha-2-macroglobulins: structure, shape, and mechanism of proteinase complex formation. J. Biol. Chem. 264, 11539–11542.
Sottrup-Jensen, L., T. E. Peterson and S. Magnusson (1981). Mechanism of proteinase complex formation with α 2-macroglobulins. Three modes of trypsin binding. FEBS Lett. 128, 127–132.
Stenman, U. H., J. Leinonen, H. Alfthan, S. Rannikko, K. Tuhkanen and O. Alfthan (1991). A complex between prostate-specific antigen and α1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostate cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 51, 222–226.
Wang, M. C., L. D. Papsidero, M. Kuriyama, L. A. Valenzuela, G. P. Murphy and T. M. Chu (1981). Prostate antigen: a new potential marker for prostate cancer. Prostate 2, 89–96.
Woodrum, D., C. French and L. B. Shamel (1996). Stability of free prostate-specific antigen in serum samples under a variety of samples collection and sample storage conditions. Urol. 48, 33–39.
Woodrum, D. and L. York (1998). Two-year stability of free and total PSA in frozen serum samples. Urol. 52, 247–251.
Wu, J. T., P. Zhang, M. E. Bandhauer, L. Wilson, M. E. Astill and J. T. Colemere (1995). Purification of PSA-ACT complex: characterization of PSA-ACT complex by various chromatographic procedures. J. Clin. Lab. Anal. 9, 25–31.
Zhang, W. M., P. Finne, J. Leinonen, S. Vesalainen, S. Nordling and S. Rannikko et al. (1998). Characterization and immunological determination of the complex between prostate-specific antigen and α 2-macroglobulin. Clin. Chem. 44, 2471–2479.
Zhang, W. M., P. Finne, J. Leinonen, S. Vesalainen, S. Nording and U-H. Stenman (1999b). Measurement of the complex between prostate-specific antigen and α 1-protease inhibitor in serum. Clin. Chem. 45, 814–821.
Zhang, W. M., P. Finne, J. Leinonen, J. Salo and U-H. Stenman (2000). Determination of prostate-specific antigen complexed to alpha-(2)-macroglobulin in serum increases the specificity of free to total PSA for prostate cancer. Urol. 56, 267–272.
Zhang, W. M., J. Leinonen, N. Kalkkinen and U-H. Stenman (1999a). Prostate-specific antigen forms a complex with and cleaves alpha 1-protease inhibitor in vitro. The Prostate 33, 87–96.